News & Updates

Show Multimedia Only
Use of RAS inhibitors associated with lower cancer risk in T2D
Use of RAS inhibitors associated with lower cancer risk in T2D
03 Oct 2022 byNatalia Reoutova

A real-world study of over 250,000 type 2 diabetes (T2D) patients from Hong Kong has found that use of renin-angiotensin-system inhibitors (RASIs) is independently associated with reduced risk of cancer, including diabetes-related cancers and cancer-specific mortality in diabetes.

Use of RAS inhibitors associated with lower cancer risk in T2D
03 Oct 2022
Alcohol consumption ups risk of CVD, all-cause mortality in men
Alcohol consumption ups risk of CVD, all-cause mortality in men
01 Oct 2022
Absence of standard modifiable cardiovascular risk factors tied to poor outcomes in type 2 AMI
Absence of standard modifiable cardiovascular risk factors tied to poor outcomes in type 2 AMI
01 Oct 2022

Among patients with type 2 acute myocardial infarction (AMI), the absence of standard modifiable cardiovascular risk factors (SMuRF) appears to worsen poor outcomes, such as mortality, stroke, and major adverse cardiovascular and cerebrovascular events (MACCE), a new study has found.

Absence of standard modifiable cardiovascular risk factors tied to poor outcomes in type 2 AMI
01 Oct 2022